CATUG Biotechnology provides one-stop CRDMO services for global gene and cell therapy drugs and nucleic acid drugs. [Photo/CATUG Biotechnology]

CATUG Biotechnology signed an agreement on March 18 to launch its International Business Innovation and R&D Center in Wuxi National Hi-Tech District (WND).

The company provides one-stop CRDMO (contract research, development and manufacturing organization) services for global gene and cell therapy drugs and nucleic acid drugs.

As part of the agreement, CATUG Biotechnology plans to build a research team of around 50 professionals in WND. The center will focus on core technology innovation and international business expansion.

CATUG's Suzhou R&D Center. [Photo/CATUG Biotechnology]

Wang Xiao, co-founder and CEO of CATUG Biotechnology, and Ren Keyun, co-founder and general manager, said WND has long placed strong emphasis on the CRDMO sector and has built a sound industrial ecosystem supported by favorable policies. They said that the district's long-term planning and sustained investment are highly encouraging.

CATUG's Wuhan R&D Center. [Photo/CATUG Biotechnology]

The company expressed strong confidence in its ongoing development in Wuxi and announced its intention to accelerate the implementation of projects, contributing to WND's goal of becoming a leading hub for the cell and gene therapy industry.

In recent years, WND has prioritized the development of landmark industries such as biomedicine. The district's biopharmaceutical sector has surpassed 100 billion yuan ($14.49 billion) in scale and ranks 18th nationwide in overall competitiveness among biopharmaceutical industrial parks.